Urothelial cancer (UC) can arise throughout the urinary system. UC is the most common form of bladder cancer and thereby one of the most common types of cancer and a significant cause of cancer-related mortality globally. In contrast, upper urinary tract urothelial carcinoma (UTUC) is a rare subtype which accounts for only 5-10% of all UCs but is often found to be invasive at diagnosis, leading to high recurrence and poor prognosis of patients with UTUC. There have been many lines of treatment to help improve the outcome, especially of advanced or metastatic disease including platinum-based first-line chemotherapy, targeted drug therapy and treatment immunotherapies including immune checkpoint inhibitors. However, the overall survival rate remains low at advanced stages and further studies are required to improve outcomes of this deadly disease.
This Research Topic aims to identify prognostic factors and novel therapies including immunotherapy in the treatment of urothelial cancer to improve prognosis and survival outcome of urothelial carcinoma patients.
Topics of interest include:
-Prognostic factors in upper urinary tract
-Targeted therapies for urothelial carcinoma
-Drug therapy for upper urinary tract urothelial carcinoma
-Impact of immunotherapy on urothelial carcinoma
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Urothelial cancer (UC) can arise throughout the urinary system. UC is the most common form of bladder cancer and thereby one of the most common types of cancer and a significant cause of cancer-related mortality globally. In contrast, upper urinary tract urothelial carcinoma (UTUC) is a rare subtype which accounts for only 5-10% of all UCs but is often found to be invasive at diagnosis, leading to high recurrence and poor prognosis of patients with UTUC. There have been many lines of treatment to help improve the outcome, especially of advanced or metastatic disease including platinum-based first-line chemotherapy, targeted drug therapy and treatment immunotherapies including immune checkpoint inhibitors. However, the overall survival rate remains low at advanced stages and further studies are required to improve outcomes of this deadly disease.
This Research Topic aims to identify prognostic factors and novel therapies including immunotherapy in the treatment of urothelial cancer to improve prognosis and survival outcome of urothelial carcinoma patients.
Topics of interest include:
-Prognostic factors in upper urinary tract
-Targeted therapies for urothelial carcinoma
-Drug therapy for upper urinary tract urothelial carcinoma
-Impact of immunotherapy on urothelial carcinoma
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
